Nicox (FRA:NXOA) Growth Rank : 1 (As of Mar. 02, 2025)

View and export this data going back to . Start your Free Trial

What is Nicox Growth Rank?

Nicox has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Nicox's Growth Rank

For the Biotechnology subindustry, Nicox's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Growth Rank distribution charts can be found below:

* The bar in red indicates where Nicox's Growth Rank falls into.

Nicox Growth Rank Related Terms

Thank you for viewing the detailed overview of Nicox's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

0RCQ:UK ALCOX:France

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines